Janux Therapeutics (JANX) R&D Day 2025 summary

Pipeline overview and program updates

• Three new programs introduced: PSMA CD28 TRACIr for prostate cancer, TROP2-targeted TRACTr for solid tumors, and a CD19 ARM for autoimmune diseases, joining existing clinical assets JANX007 and JANX008.

• PSMA CD28 TRACIr is designed for combination with JANX007 to enhance and prolong anti-tumor T cell response in prostate cancer.

• TROP2 TRACTr leverages learnings from JANX007/008 and targets a broad range of solid tumors with high unmet need.

• CD19 ARM platform aims to provide robust, durable B cell depletion for autoimmune diseases, with additional programs targeting BCMA, CD20, and BAFF receptor in development.

Clinical trial data and development milestones

• JANX007 has shown unprecedented PSA decline and robust clinical activity in late-stage prostate cancer, with 100% PSA50s and 63% PSA90s, and durable responses beyond 12 weeks.

• PSMA CD28 TRACIr is in IND-enabling studies, with IND filing planned for H1 next year and patient dosing in H2.

• TROP2 TRACTr is entering IND-enabling studies this year, aiming for first-in-class status and broad tumor applicability.

• CD19 ARM first-in-human Phase 1 study is planned for the first half of next year, with regulatory filings in Q4 this year.

R&D strategy and innovation priorities

• Focus on modular, tumor-activated, and masked bispecific platforms to maximize efficacy and safety.

• Leveraging clinical and non-clinical learnings to accelerate development and expand into new indications.

• Emphasis on outpatient, subcutaneous dosing and broad dose range to optimize patient convenience and safety.